Modulation of Luciferase Production in Melanoma Cells in vitro


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Reporter proteins find increasing application in biomedical studies in vitro and in vivo. However, to correctly interpret the results based on their use, it is important to understand whether reporter protein production is modulated in model cells and in what conditions such modulation may occur. Reporter activity was studied in Mel IL melanoma cells transiently transfected with a pCpG vector-based plasmid construct expressing firefly luciferase. Luciferase expression quickly dropped during the first two culture passages, which were followed by a quasi-stable period, when luciferase expression relatively slightly decreased with time. Phases of maximal and minimal luciferase production, which corresponded to the exponential and stationary growth phases, respectively, were observed during batch culture. When the medium was changed, luciferase production was stimulated in the stationary, but not exponential, cell growth phase. Severe hypoxia (0.1% O2) decreased the luciferase amount, suggesting substantial modulation of cell metabolism in total and luciferase production in particular. The targeted drug vemurafenib suppressed the luciferase production in Mel IL cells, whereas DMSO, which is often used as a drug solvent in experiments with cells, stimulated the luciferase production. Based on the results, it was hypothesized that modulation of reporter protein production in mammalian cells reflects the adaptation of intracellular metabolism to external conditions and may be a source of incorrect interpretations of experiments using reporter proteins.

作者简介

O. Kandarakov

Engelhardt Institute of Molecular Biology, Russian Academy of Sciences; Blokhin Cancer Research Center, Russian Academy of Medical Sciences

编辑信件的主要联系方式.
Email: oleg.kandarakov@gmail.com
俄罗斯联邦, Moscow, 119991; Moscow, 115478

A. Bruter

Engelhardt Institute of Molecular Biology, Russian Academy of Sciences; Blokhin Cancer Research Center, Russian Academy of Medical Sciences

Email: oleg.kandarakov@gmail.com
俄罗斯联邦, Moscow, 119991; Moscow, 115478

A. Belyavsky

Engelhardt Institute of Molecular Biology, Russian Academy of Sciences

Email: oleg.kandarakov@gmail.com
俄罗斯联邦, Moscow, 119991

补充文件

附件文件
动作
1. JATS XML

版权所有 © Pleiades Publishing, Inc., 2018